title: [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
abstract: OBJECTIVE
  To study the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and toxicities after high-dose methotrexate (HD-MTX) infusion in children with acute lymphocytic leukemia (ALL).
  
  
  METHODS
  MTHFR variants in 52 children with ALL were determined by reverse transcriptase-polymerase chain reaction-denaturing gradient gel electrophoresis and sequencing. Toxicities of children who received HD-MTX chemotherapy were evaluated according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC).
  
  
  RESULTS
  The children carrying MTHFR 1298AC had a higher risk of developing thrombocytopenia compared with the carriers of the 1298 AA genotype (OR=13.7, 95%CI=1.18-159.36, P=0.036). There was no significant difference in HD-MTX chemotherapy-related adverse effects between the patients with different MTHFR C677T or G1793A genotypes.
  
  
  CONCLUSIONS
  MTHFR A1298C polymorohism may associate with the toxicity of HD-MTX chemotherapy in children with ALL.
authors.affiliation: Shenzhen Children's Hospital, Zunyi Medical College, Shenzhen, Guangdong, China.
authors.forename: Miao-Miao
authors.initials: MM
authors.lastname: Zheng
authors.forename: Li-Jie
authors.initials: LJ
authors.lastname: Yue
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Chen
authors.forename: Fei-Qiu
authors.initials: FQ
authors.lastname: Wen
authors.forename: Chang-Gang
authors.initials: CG
authors.lastname: Li
authors.forename: Chun-Lan
authors.initials: CL
authors.lastname: Yang
authors.forename: Cai
authors.initials: C
authors.lastname: Xie
authors.forename: Hui
authors.initials: H
authors.lastname: Ding
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000964:Antimetabolites, Antineoplastic; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate